retatrutide phase 2 diabetes trial for Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type Collection_clearance Quantity:1 🧠 Researchers are exploring

retatrutide phase 2 diabetes trial for Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type Collection_clearance Quantity:1 🧠 Researchers are exploring

🧠 Researchers are exploring whether GLP-1 medications used for #diabetes and weight loss could treat #Alzheimers and addiction, but public concerns persist about long-term safety. 🔗 Read the full article at beingpatient.com #

It works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite

Collection_clearance

Quantity:1

Importantly, receptor internalization dynamics modulate signaling duration and bias